Cellomatics was delighted to be recognised at the recent One Nucleus Awards 2024, having been shortlisted in the Best Performing R&D Service Provider of the Year category.
Opposition was fierce. Cellomatics was alongside o2h discovery, a large CRO with research centres in Cambridge and India, and Abzena, again a large CRO with centres in the USA and Cambridge. Our congratulations to Abzena.
“We were in excellent company,” comments Shailendra Singh, CEO and Founder of Cellomatics, “and I’m delighted that we were able to represent our region as well as ourselves.” He adds: “It’s important to be able to showcase what we do here in the Midlands and put the region well and truly on the life sciences map. Our recognition is the region’s recognition.”
The awards criteria acknowledges organisations that have demonstrated remarkable achievements in the field of drug discovery services. This recognition highlights Cellomatics’ dedication and understanding of the sector and its progress to date.
The One Nucleus Awards 2024 are a reflection of the breadth of R&D, investment, service provision and enabling support across the stakeholders with “Performance of the Year” being recognised in each of the twelve categories. Categories ranged from Facilities Provider of the Year to Technology Transfer Office of the Year. The Awards categories deliberately break with tradition in order to recognise the full extent of the healthcare/life sciences eco system.
The Awards themselves took place at No.11 Cavendish Square, London on 21 March 2024 where members of the senior management team, Dr Lara De Tomasi and Dr Alex Timmis, joined Shailendra to celebrate the event.
